Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.

@article{Kalil2011InfluenceOS,
  title={Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.},
  author={Andre C. Kalil and Steven P. Larosa and Jagadish Gogate and Melvyn Lynn and Steven M. Opal},
  journal={Shock},
  year={2011},
  volume={36 4},
  pages={327-31}
}
Disease severity varies widely in patients with severe sepsis. Eritoran tetrasodium (E5564), a TLR4 antagonist, blocks the binding of endotoxin and is being evaluated as a novel therapy for severe sepsis. This analysis aimed to assess the efficacy of eritoran based on severity of illness and similar effects in other recent sepsis trials. Prospective covariates from a randomized, double-blind, placebo-controlled, phase 2 trial were analyzed for treatment interaction measured by 28-day mortality… CONTINUE READING